Keywords: aronex, tests, atragen, renal, cancer, initiated, phase
Aronex tests Atragen in renal cancer
Article | 21 January 1999
Aronex has initiated a Phase I/II study of its proprietary injectableformulation of all-trans-retinoic acid, Atragen, in combination with interferon ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- US Supreme Court says patent settlement can "sometimes" be illegal
- Negative US patent ruling for Novo Nordisk on Prandin
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
